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Proteolytic enzymes released from granulocytes upon stimulation with the chemotactic N-formyl peptide FNLPNTL (in 
the presence of cytochalasin B)prevented activation of tumor cell single-chain urokinase-type lasminogen activator (pro- 
uPA) by plasmin. Elastase was identified by the use of eglin C (elastase inhibitor) and a monoclonai ntibody to elastase 
as the functional proteolytic enzyme in granulocyte supernatants. Action of purified granulocyte elastase on pro-uPA 
generated enzymatically inactive two-chain uPA linked by disulfide bridges which was indistinguishable bySDS-PAGE 
from plasmin-generated HMW-uPA. The major elastase cleavage site in pro-uPA was located between Ile 159 and Ilca°°; 
a minor one between Thr 1~5 and Thr TM. Elastase cannot substitute for plasmin in the proteolytic activation of pro-uPA 
to enzymatically active HMW-uPA. However, when pro-uPA was first activated by plasmin to form enzymatically active 
HMW-uPA, this enzymatic activity was not impaired by sfibsequent elastase treatment. 
Prourokinase; Plasminogen activator; Elastase; Granulocyte; Chemotactic peptide; N-terminal amino acid sequence determination 
1. INTRODUCTION 
Tumor cells produce the urokinase-type 
plasminogen activator (uPA) as an inactive single- 
chain precursor molecule (pro-uPA) which is con- 
verted to enzymaticaily active two-chain HMW- 
uPA by small amounts of plasmin [1,2]. HMW- 
uPA is a serine protease composed of two polypep- 
tide chains (Mr = 20 000 and 34 000) connected by 
a disulfide bridge [3]. Conversion of plasminogen 
to the enzymatically active serine protease plasmin 
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by HMW-uPA is a general mechanism which in- 
itiates pericellular proteolysis [1]. Plasminogen ac- 
tivation by HMW-uPA is involved in tissue and 
stroma degradation i a number of benign as well 
as malignant conditions [1]. Recent studies 
demonstrated that HMW-uPA is a potent 
chemotactic factor for granulocytes in vivo in addi- 
tion to tumor stroma breakdown products which 
may also attract granulocytes into the tumor tissue 
[4]. Phagocytic ells have been identified by im- 
munohistochemistry in tumors of the uterine cervix 
[5]. Granulocytes contain enzymatically active pro- 
teases: elastase, collagenase, and gelatinase, which 
are released by chemotatic activation [6]. Each of 
these proteases i  able to attack components of the 
extracellular matrix [6]. We now report that 
granulocyte lastase, released upon stimulation 
with chemotactic peptides, degrades tumor pro- 
uPA to an enzymaticaily nactive uPA form which 
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cannot be converted to enzymatically active HMW- 
uPA by plasmin. 
2. MATERIALS AND METHODS 
2.1. Materials 
Reagents were obtained from the sources indicated in paren- 
theses. Pro-uPA (spec. act. of 135 000 U/mg) produced by 
kidney tumor cell line TCL 598 (Sandoz, Nfirnberg, FRG). 
HMW-uPA (Serono, Freiburg, FRG). Human granulocyte 
elastase (Protogen, L-~iufelfingen, Switzerland). Human plasmin 
and fibrinogen (KabiVitrum, Miinchen). Prestained gel stand- 
ards (Pharmacia, Freiburg, FRG). Aprotinin and test-thrombin 
(Behring Werke, Marburg, FRG). Bovine serum albumin (BSA) 
and cytochalasin B (Sigma, Miinchen, FRG). 
N- formyl-Nle-Leu-Phe-Nle-Tyr-Lys (FNLPNTL) and 
substrates S-2444 and methoxysuccinyl-Ala-Ala-Pro-Val- 
paranitroanilide (Bachem, Hannover, FRG). Eglin C was 
donated by Dr H. Fritz, Ludwig Maximilians University, Miin- 
chen, FRG, and murine monoclonal antibody to human 
granulocyte lastase by Dr T. Cotter, Maynooth, Ireland. All 
other reagents were of analytical grade. 
2.2. Methods 
2.2.1. SDS-Page 
SDS-PAGE was performed according to Laemmli [7] apply- 
ing 15070 acrylamide gels. Prestained proteins served as 
molecular weight markers. Samples were reduced by 10 mM 
2-mercaptoethanol. Proteins were stained with Coomassie blue 
R-250 (Serva, Heidelberg, FRG) and destained with 707o acetic 
acid. 
2.2.2. Assays of enzymatic activity of HMW-uPA 
Amidolytic activity of HMW-uPA was measured in 0.1 M 
Tris-HCl, pH 8.8, containing 0.1 M NaCl and 0.01% BSA using 
the synthetic substrate S-2444 [8]. Fibrin clot lysis assay was per- 
formed according to Kruithof et al. [9] using fibrin gels which 
contain excess of plasminogen. Lysis volume in tubes (r = 5 mm) 
was calculated in °10 of total gel volume. 
2.2.3. Purification of human peripheral blood granulocytes 
Granulocytes were purified according to Boyum [10]. Viabili- 
ty was >98070 as judged by trypan blue exclusion. Con- 
taminating erythrocytes were lysed by short exposure (5 min) of 
cells to lysis buffer (160 mM NH4CI, 12 mM NaHCO3, 0.1 mM 
EDTA, pH 7.3). Cells were stored at room temperature in
PBS-2% BSA without calcium and magnesium salts. 
2.2.4. Degranulation of granulocytes by stimulation with the 
N-formyl chemotactic peptide FNLPNTL in the presence 
of cytochalasin B 
5 × 106 granulocytes were incubated in 1 ml PBS (containing 
0.5 mM MgCl2, 1 mM CaCl~, 0.1% BSA) with 5/zg cytochalasin 
B (5 rain, 37°C). 10/~l of 10- 6 M FNLPNTL was added (30 min, 
37°C) and supernatants collected by low speed centrifugation 
(250 × g, 5 min). Elastase activity was assessed by using 
methoxysuccinyl-Ala-Ala-Pro-Val-paranitroanilide s the hu- 
man elastase specific substrate [11]. 
2.2.5. Identification of proteolytic leavage site in pro-uPA by 
sequence analysis 
370/~g of pro-uPA in 1 ml PBS were digested with 20 #g (0.5 
U) of purified granulocyte elastase in 200/~1 of 62 mM Tris-HCl, 
pH 7.5 (30 min, 37°C). Digestion of pro-uPA into two-chain 
uPA was verified by SDS-PAGE. The digested sample and an 
undigested control sample were dialyzed against 3070 acetic acid. 
An aliquot of each sample was sequenced by Edman degrada- 
tion in a prototype spinning-cup sequenator [12]. The amino 
acid derivatives were identified by isocratic HPLC analysis. 
3. RESULTS 
Supernatants of human granulocytes, which had 
been stimulated with the N-formyl chemotactic 
peptide FNLPNTL, contained proteases which 
Table 1 
Identification of elastase in supernatants of stimulated human 
granulocytes as the functional protease to degrade tumor cell 
pro-uPA 
Assay 
Stimulus Fibrin clot lysis Amidolytic activity 
(ml) (U/ml) 
PBS 
+ Cytochalasin B 
+ Cytochalasin B 
and FNLPNTL 
+ Cytochalasin B 
and FNLPNTL, 
then addition of 
eglin C 
+ Cytochalasin B 
and FNLPNTL, 
then adition of 
antibody to 
elastase 
0.47 _+ 0.018 16.0 _+ 2.4 
0.49 _+ 0.065 14.6 _ 4.6 
0.06 +_ 0.012 2.1 _+ 1.1 
0.48 _+ 0.015 21.0 + 2.7 
0.47 _+ 0.015 15.8 +_ 2.8 
5 x 106 granulocytes/ml PBS containing 0.5 mM MgCI2, 1 
mM CaCl2, and 0.1070 BSA were pretreated with 5 #g 
cytochalasin B/ml ( 5 rain, 37°C) prior to the addition of l0 - 8 
M FNLPNTL (30 rain, 37°C). Supernatants were collected by 
low speed centrifugation and then incubated with eglin C (12 
/~M) or monoclonal antibody to elastase (15/zM) for 30 min, 
37°C. Cells which had been treated with buffer or cytochalasin 
B, only, served as controls. Aliquots of 30/zl or pro-uPA (500 
ng) were mixed with 30/zl of the various cell supernatants (30 
min, 37°C) and then subjected to fibrin clot assay as described 
in section 2. For assay of amidolytic activity with substrate 
S-2444, 0.3 nM of plasmin was added. The reaction was stopped 
by addition of 200 KIU aprotinin/ml. Average values obtained 
from 4 different donors are expressed _+ standard eviation 
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prevented conversion of tumor cell p ro -uPA to en- 
zymatically active HMW-uPA (table 1). When pro- 
uPA was treated with supernatants from 
granulocytes, which were stimulated with 10-s  M 
FNLPNTL  in the presence of cytochalasin B, pro- 
uPA was impaired in such a way that the subse- 
quent treatment with plasmin did not result in an 
enzymatically active HMW-uPA.  Preincubat ion of
cell supernatants,  however, with eglin C (inhibitor 
for elastase and cathepsin G [13]) or an ant ibody to 
the enzymatically active region of elastase, 
prevented the inactivation of pro -uPA by the cell 
supernatant.  Thus by these inhibit ion experiments 
the proteolytic activity in granulocyte supernatants 
was identified as elastase. 
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Exposure of pro -uPA to purified granulocyte 
elastase (0 - 6/~g/ml, 30 min,  37°C) did not result 
in an enzymatically active HMW-uPA.  Hence, 
elastase cannot substitute for plasmin in pro-uPA 
activation in vitro. Moreover, human elastase at a 
protein weight ratio of 1.5:10 for elastase to pro- 
uPA was sufficient o prevent activation of pro- 
uPA in a way that subsequent plasmin treatment 
did not generate nzymatically active HMW-uPA 
(fig. 1). This confirms the results obtained with the 
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Fig.1. Effect of purified granulocyte elastase on pro-uPA and 
HMW-uPA. Elastase (0-200 nM in PBS containing 0.5 mM 
MgCl2, I mM CaClz, and 0.1% BSA) was incubated with 370 ng 
HMW-uPA/50 pl (30 min, 37 ° C) and then treated with 0.13 nM 
plasmin (45 min, 37°C). Plasmin reaction was stopped by the 
addition of 200 KIU aprotinin/ml. Amidolytic activity was 
measured as described in section 2. For fibrinolytic assay 
elastase (0-200 nM) was incubated with 500 ng pro-uPA as 
described for the amidolytic assay and then layered on top of 
fibrin gels as described insection 2. Values are representative for 
cell supernatants collected from 3 different donors. 
FRONT 
1 2 
B-chain 
A-chains 
Fig. 2. SDS-PAGE of pro-uPA and HMW-uPA treated with 
elastase or plasmin. 5 ~g of pro-uPA (A) and HMW-uPA (B) 
were treated with 0.13 ~g of plasmin or 0.37 /~g of purified 
granulocyte elastase in30 ~1 of PBS for 30 min, 37°C, and then 
heated with 20 ~1 sample buffer containing 2-mercaptoethanol 
for 5 min, 100°C. Polypeptide chains were separated by SDS- 
PAGE (15% acrylamide) and stained with Coomassie blue 
R-250. Please, note that he prominent band above the B-chain 
is not part of pro-uPA. This band does not stain with antibodies 
to uPA in Western blots and represents albumin which was ad- 
ded to pro-uPA by the manufacturer asa stabilizing protein. (A) 
pro-uPa was treated with buffer (lane 1); ¢lastase (lane 2); 
plasmin (lane 3). (B) HMW-uPA was treated with buffer (lane 
1); elastase (lane 2). 
85 
Volume 255, number 1 FEBS LETTERS September 1989 
Table 2 
Identification fgranulocyte elastase cleavage sites in pro-uPA by N-terminal mino acid sequence d termination 
Sample N-terminal sequence 
pro-uPA 
Elastase-treated 
pro-uPA 
1 5 10 15 
Ser-Asn-Glu-Leu-His-Gln-Val-Pro-Ser-Asn-Cys-Asp-Cys-Leu-Asn-Gly- 
1 5 10 15 
Ser-Asn-Glu-Leu-His-Gln-Val-Pro-Ser-Asn-Cys-Asp-Cys-Leu-Asn-Gly- 
t60 165 170 175 
lle-Gly-Gly-Glu-Phe-Thr-Thr-Ile-Glu-Asn-Gln-Pro-Trp-Phe-Ala-Ala- 
166 170 175 180 
Thr-Ile-Glu-Asn-Gln-Pro-Trp-Phe-Ala-Ala-Ile-Tyr-Arg-Arg-His-Arg- 
A sample of 370/zg pro-uPA, dissolved in 1 ml PBS, was incubated with 20 #g (0.5 U) of granulocyte elastase (30 min, 37°C), acidified 
with acetic acid to pH 3 and then dialyzed extensively against 3% acetic acid. Undigested pro-uPA was also acidified. An aliquot each 
of the samples (about 1 nmol) was subjected to sequence analysis for 16 cycles. The sequence of human serum albumin, included as 
a stabilizer in the uPA preparation, was also clearly observed in both samples (data not shown). 
supernatants of stimulated granulocytes. En- 
zymatically active HMW-uPA (obtained from pro- 
uPA by plasmin treatment or the commercially 
available HMW-uPA purified from urine) was not 
appreciably affected by subsequent elastase treat- 
ment. Human granulocytes also produce pro-uPA 
which is stored in specific granules [14]. However, 
under the conditions applied (short-term stimula- 
tion) no significant release of pro-uPA into cell 
supernatants of stimulated granulocytes was 
detected by ELISA or enzymatic assays (data not 
shown). 
Proteolytic action of elastase on pro-UPA was 
verified by SDS-PAGE (fig.2A). Similar to 
plasmin, elastase splits pro-uPA into two chains of 
Mr = 34 000 (B-chain) and 20 000 (A-chain). 
When HMW-uPA was treated with the same con- 
centrations of plasmin or elastase as described for 
pro-uPA, no significant degradation of the 
polypeptide chains was observed (fig.2B). At a 
high concentration of elastase (1 ttM), however, 
significant breakdown of the A-chain as well as the 
B-chain was observed (data not shown). 
The elastase cleavage site in pro-uPA was 
evaluated by N-terminal amino acid sequence 
determination. The unfractionated igest was 
analyzed in parallel with untreated pro-uPA (table 
2). In the undigested pro-uPA the known sequence 
(16 amino acids) [3] was found. In the elastase- 
treated pro-uPA two additional N-terminals were 
detected. The prominent cleavage site is between 
Ile 159 and Ile 16°, the second minor one between 
Thr 165 and Thr 166 (approximate ratio of 5:1). The 
new sequences tarted with Ile 16° and Thr ~66, 
respectively. This is one and seven residues behind 
the beginning of the plasmin-derived B-chain. 
4. DISCUSSION 
Human phagocytic ells are mediators of tissue- 
destroying events in inflammation and tumor 
spread [6]. These processes are linked to the 
phagocyte's ability to release toxic agents or en- 
zymes upon receptor-mediated stimulation which 
can dissolve extracellular matrix components and 
destroy cells. More than 50 of such compounds 
have been identified including the proteases 
elastase, collagenase, and gelatinase [6]. 
Chemotactically attracted phagocytic cells are 
found in the tumor tissue and the stroma sur- 
rounding the tumor nests [5]. Tumor cells secrete 
the proenzyme form pro-uPA of the urokinase- 
type plasminogen activator [1,2]. 
The conversion of pro-uPA to enzymatically ac- 
tive HMW-uPA is limited to the specificity of the 
enzyme applied. Plasmin converts pro-uPA into 
enzymatically active HMW-uPA [1-3]. Degrada- 
tion of the tumor stroma is initiated by plasmin 
which is generated from plasminogen by the action 
of HMW-uPA [1]. Trypsin and plasma kallikrein 
may substitute for plasmin [15]. Proteolytic action 
of thrombin [15,16] and as shown in the present 
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report, granulocyte elastase, on pro-uPA results in 
enzymatically inactive uPA-forms which are resis- 
tant to subsequent activation by plasmin. Active 
and inactive forms of uPA were indistinguishable 
by SDS-PAGE. Plasmin and trypsin specifically 
cleave the Lys 15s- Ile ~59 peptide bond within the 
single chain pro-uPA [15]. Thrombin specifically 
cleaves the Arg~6-PheX57 peptide bond which is 
located two amino acid residues prior to this bond 
[15] (fig.3). 
In the present work evidence is presented that 
human granulocyte lastase specifically cleaves 
pro-uPA at the peptide bonds Ile~59-Ile~6° and 
Thr165-Thr 166, the former cleavage site being 
predominant ( able 2; fig.3). These cleavage sites 
are located just behind the plasmin-cleavage site 
and yield A- and B-chains of similar length as 
shown on SDS-PAGE for plasmin degradation. 
Cleavage of pro-uPA within the disulfide-linked 
domain by proteolytic enzymes will cause a confor- 
mational change within the molecule [15-17]. 
Depending on which peptide bond is cleaved, an 
enzymatically active or inactive two-chain molecule 
is generated. Elastase was identified as the func- 
tional enzyme in cell supernatants of chemotac- 
tically activated human granulocytes, as both, eglin 
C and a monoclonal ntibody to elastase, blocked 
proteolysis of pro-uPA by these cell supernatants. 
Heiple and Ossowski [14] also reported on the 
destructive potential of cell supernatants of 
stimulated granulocytes on pro-uPA without iden- 
tifying the components involved. The inactivation 
capacity of these enzymes was inhibited by the 
serine protease inhibitor diisopropylfluorophos- 
phate (DFP). Heiple's and our results upport he 
notion that granulocyte elastase is one of the key 
enzymes which may inactivate pro-uPA released by 
cells. 
Elastase content in phagocytic cells can be iden- 
tified by immunohistochemistry within the tumor 
stroma nd close to tumor cells of breast cancer pa- 
tients (Schmitt and J/inicke, unpublished). De- 
pending on which enzyme, elastase or plasmin, 
cleaves pro-uPA, enzymatically inactive uPA or 
active HMW-uPA will be generated. Interestingly, 
enzymatically active HMW-uPA (which has been 
formed by plasmin treatment ofpro-uPA) is not in- 
activated by subsequent elastase [17] or thrombin 
[16] action. 
Although elastase does not inactivate HMW- 
uPA, the enzymatic activity of HMW-uPA in solu- 
tion may be inhibited by the specific plasminogen 
activator inhibitors PAI-1 and PAI-2 [1,2]. 
Therefore, separate mechanisms appear to exist 
which regulate pro-uPA conversion and HMW- 
uPA activity: inactivation of (i) pro-uPA by 
granulocyte elastase or thrombin and (ii) HMW- 
uPA by plasminogen activator inhibitors PAI-1 or 
PAI-2. HMW-uPA bound to receptors on tumor 
cells is supposed to be involved in tumor growth, 
malignant invasion, degradation of the tumor 
stroma and metastasis [1,2]. Inactivation of pro- 
uPA by granulocyte elastase, in addition to inac- 
tivation of HMW-uPA by PAI-1/2, therefore may 
delay the proteolytic processes in tumor-associated 
fibrinolysis [18]. 
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